Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseNatural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the AgedAntibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathyImmunotherapeutic approaches for Alzheimer's diseaseNeuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures.Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencyOligomeric tau-targeted immunotherapy in Tg4510 mice.Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.Novel immunological approaches for the treatment of Alzheimer's disease.Antibody-derived in vivo imaging of tau pathology.Tau aggregation and its interplay with amyloid-β.γ-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway.Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson's Disease-like DementiaDetecting tau in serum of transgenic animal models after tau immunotherapy treatment.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau passive immunization inhibits not only tau but also Aβ pathologyCytosolic Fc receptor TRIM21 inhibits seeded tau aggregation.Harnessing the immune system for treatment and detection of tau pathology.Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease.Invited review: Drug development for tauopathies.Tau Immunotherapy.Tau and neurodegenerative disease: the story so far.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approachA Therapeutic Antiviral Antibody Inhibits the Anterograde Directed Neuron-to-Cell Spread of Herpes Simplex Virus and Protects against Ocular Disease.Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer's disease subjects: an exploratory study.Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex.Tau Proteins and Tauopathies in Alzheimer's Disease.RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration.Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.Tau-based therapies in neurodegeneration: opportunities and challenges.Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.
P2860
Q26739412-4548CF8E-ED95-4EF4-8C33-9E56470E2EC6Q26752508-66E9050B-6FDA-4D5D-9378-7ED4459FCB48Q27316185-42B26CD1-6038-484A-89F8-69F005C7C790Q28081278-D77FA25D-FF44-4ADD-936C-7B8631E1CDBBQ30587642-09BB5152-E72B-4C0B-9420-5E79686D3120Q30805841-3D09B748-127E-40D1-B6CE-27C0E44CDA05Q33603862-C09DE735-E148-4382-AC57-C5292E54F01BQ33640390-04F07053-F09C-4AE5-BF24-C54B9A0A1504Q33846761-4E4558D4-177E-4E93-BD54-9DD17B48ACF0Q34507534-CA1389CD-1638-4248-A082-E6F0FA9A527CQ34562675-A74FFF7A-9BD3-4F2A-A651-F1D00F6AADB6Q34664345-9584B5C2-C7CA-4932-A612-AEF55DCD8E52Q35008256-52204069-3BDA-4093-9ECD-4BA84977CF79Q35111136-B0FDB902-C68A-4180-B22A-9A0BAA58FA9EQ36065130-E87ED1B2-71E6-41AC-B73B-06D92AFD7115Q36146776-95C3AEC4-A28A-4A27-B154-71D127BF1D75Q36395623-C952E645-C44D-46CE-AF95-220A360CFC1CQ36484413-AB9BD336-94B6-4CC3-A7E2-9227D16CE8BCQ37579019-84500DEE-0137-4FF1-BA9F-372B7525FAFAQ37598940-3A225BEE-54DE-4171-BB69-5DD08B729C8BQ38194049-DBFA6E43-346D-4D23-BF75-E60879C91417Q38204620-6A795A06-0CA8-4D8E-B4BD-2AB45308706AQ38246262-9BEE669E-0DBF-4BC1-BD63-C7298A736FC3Q38263698-9D309219-FD6A-46CC-A09C-C796ECF01A66Q38628672-7B568D9F-7C1F-4877-A3C5-3D1398F4908AQ38658752-9E5399D9-52F5-4836-8311-99B26DDC48E6Q38715233-F4A75AB6-DED0-489D-819C-DDAE8CD549ADQ38787483-1D7054B9-66FB-41E6-AD6A-92813DFB6A77Q38983187-BEF2857C-687F-476E-95EE-B3BEE364DC06Q41170285-4C7937DB-D930-4691-9170-955AA3B78A0CQ41629521-9D3426B9-456D-42FA-A83F-93239FC72D7CQ45324468-36DEE0C2-12E7-4B2F-BD01-15D71FF8D0B5Q46383545-64389C31-377B-4E19-9DFE-49025E5543A9Q47099501-2AA726E6-6066-427D-81C6-F9E91C79D2B6Q47202386-1C69FEA2-9B4C-49E2-B214-3FF260492FE8Q47233523-161F53D7-BD1B-453B-B295-3D8B78C0B87DQ47423589-A694C259-2C56-4A6D-A823-88C58CAAAAE7Q47547728-ACAD2B31-32FF-4820-AC96-84D521D50EF7Q47689697-1B1819C6-CF52-41EB-8B2E-20A81CA49E6EQ48624391-ED53B930-1E44-4CD3-9FBE-DF402EEB50DA
P2860
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibody uptake into neurons o ...... r acute tau protein clearance.
@en
Antibody uptake into neurons o ...... r acute tau protein clearance.
@nl
type
label
Antibody uptake into neurons o ...... r acute tau protein clearance.
@en
Antibody uptake into neurons o ...... r acute tau protein clearance.
@nl
prefLabel
Antibody uptake into neurons o ...... r acute tau protein clearance.
@en
Antibody uptake into neurons o ...... r acute tau protein clearance.
@nl
P2860
P356
P1476
Antibody uptake into neurons o ...... or acute tau protein clearance
@en
P2093
Hameetha B R Sait
Jiaping Gu
P2860
P304
35452-35465
P356
10.1074/JBC.M113.491001
P407
P577
2013-10-25T00:00:00Z